# A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate

> **NCT05349435** · PHASE1 · TERMINATED · sponsor: **Liminal BioSciences Ltd.** · enrollment: 8 (actual)

## Conditions studied

- Hyperammonemia

## Interventions

- **DRUG:** Fezagepras
- **DRUG:** Sodium phenylbutyrate

## Key facts

- **NCT ID:** NCT05349435
- **Lead sponsor:** Liminal BioSciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-13
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Sponsor has decided to discontinue development of fezegepras based on initial pharmacokinetic results
- **Last updated:** 2022-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349435, "A Healthy Volunteer Study to Compare Fezagepras (PBI-4050) With Sodium Phenylbutyrate". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05349435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*